학술논문
Use of Venetoclax in Patients with Relapsed or Refractory Acute Myeloid Leukemia: The PETHEMA Registry Experience
Document Type
article
Author
Jorge Labrador; Miriam Saiz-Rodríguez; Dunia de Miguel; Almudena de Laiglesia; Carlos Rodríguez-Medina; María Belén Vidriales; Manuel Pérez-Encinas; María José Sánchez-Sánchez; Rebeca Cuello; Alicia Roldán-Pérez; Susana Vives; Gonzalo Benzo-Callejo; Mercedes Colorado; María García-Fortes; María José Sayas; Carmen Olivier; Isabel Recio; Diego Conde-Royo; Álvaro Bienert-García; María Vahi; Carmen Muñoz-García; Cristina Seri-Merino; Mar Tormo; Ferran Vall-llovera; María-Ángeles Foncillas; David Martínez-Cuadrón; Miguel Ángel Sanz; Pau Montesinos
Source
Cancers, Vol 14, Iss 7, p 1734 (2022)
Subject
Language
English
ISSN
2072-6694
Abstract
The effectiveness of venetoclax (VEN) in relapsed or refractory acute myeloid leukemia (RR-AML) has not been well established. This retrospective, multicenter, observational database studied the effectiveness of VEN in a cohort of 51 RR-AML patients and evaluated for predictors of response and overall survival (OS). The median age was 68 years, most were at high risk, 61% received ≥2 therapies for AML, 49% had received hypomethylating agents, and ECOG was ≥2 in 52%. Complete remission (CR) rate, including CR with incomplete hematological recovery (CRi), was 12.4%. Additionally, 10.4% experienced partial response (PR). The CR/CRi was higher in combination with azacitidine (AZA; 17.9%) than with decitabine (DEC; 6.7%) and low-dose cytarabine (LDAC; 0%). Mutated NPM1 was associated with increased CR/CRi. Median OS was 104 days (95% CI: 56–151). For the combination with AZA, DEC, and LDAC, median OS was 120 days, 104 days, and 69 days, respectively; p = 0.875. Treatment response and ECOG 0 influenced OS in a multivariate model. A total of 28% of patients required interruption of VEN because of toxicity. Our real-life series describes a marginal probability of CR/CRi and poor OS after VEN-based salvage. Patients included had very poor-risk features and were heavily pretreated. The small percentage of responders did not reach the median OS.